NASDAQ : SILO
Silo Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.25 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.04M |
| Enterprise Value | -3.19M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.59M |
| Shares Outstanding | 1.59M |
| Shares Change (YoY) | +170.50% |
| Shares Change (QoQ) | +20.19% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 7.71% |
| Float | 1.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.13 |
| Forward PS | n/a |
| PB Ratio | 0.28 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.36 |
| Quick Ratio | 4.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -112.03 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -91.23% |
| Return on Assets (ROA) | -44.25% |
| Return on Invested Capital (ROIC) | -56.89% |
| Return on Capital Employed (ROCE) | -91.31% |
| Weighted Average Cost of Capital (WACC) | 9.25% |
| Revenue Per Employee | $18,026 |
| Profits Per Employee | -$1.49M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -84.76% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 4.56 |
| Relative Strength Index (RSI) | 34.16 |
| Average Volume (20 Days) | 34,671 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 22,078 |
| Short Previous Month | 34,870 |
| Short % of Shares Out | 1.39% |
| Short % of Float | 1.40% |
| Short Ratio (days to cover) | 0.19 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 54,077 |
| Gross Profit | -7,987 |
| Operating Income | -4.46M |
| Pretax Income | -4.47M |
| Net Income | -4.47M |
| EBITDA | -4.45M |
| EBIT | -4.46M |
| Loss Per Share | -$5.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.23M |
| Total Debt | n/a |
| Net Cash | 5.23M |
| Net Cash Per Share | $3.29 |
| Equity (Book Value) | 4.89M |
| Book Value Per Share | 4.33 |
| Working Capital | 4.65M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 11,750 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.34M |
| FCF Per Share | -$2.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | -14.77% |
| Operating Margin | -8,250.46% |
| Pretax Margin | -8,269.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -170.50% |
| Shareholder Yield | -170.50% |
| Earnings Yield | -394.30% |
| FCF Yield | -170.98% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | -0.05% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 3, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.34 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |